A phase I clinical trial has also confirmed that the combined strategy of RFA and anti-CTLA-4 treatments against human hepatocellular carcinoma can present a synergistic anti-tumor effect and an increasing number of CD8+TILs [42]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.